(0.00%) 5 308.21 points
(0.00%) 39 807 points
(-0.06%) 16 784 points
(-0.88%) $79.10
(-2.07%) $2.69
(-0.48%) $2 426.70
(-1.05%) $32.09
(-0.21%) $1 061.50
(0.11%) $0.922
(-0.27%) $10.67
(-0.01%) $0.787
(-0.38%) $90.33
-1.96% $ 3.00
Live Chart Being Loaded With Signals
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke...
Stats | |
---|---|
Volumen de hoy | 4 854.00 |
Volumen promedio | 40 400.00 |
Capitalización de mercado | 113.89M |
EPS | $0 ( 2024-05-20 ) |
Próxima fecha de ganancias | ( $-0.160 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.00 |
ATR14 | $0.0170 (0.57%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-22 | Lorianne Masuoka K. | Buy | 285 000 | Stock option (right to buy) |
2024-01-22 | Lorianne Masuoka K. | Buy | 0 | |
2024-01-02 | Semba Charles Pauling | Buy | 9 375 | Voting Common Shares, no par value per share |
2024-01-02 | Kuntz Richard | Buy | 14 285 | Voting Common Shares, no par value per share |
2024-01-02 | Pilnik Richard D. | Buy | 30 357 | Voting Common Shares, no par value per share |
INSIDER POWER |
---|
54.04 |
Last 91 transactions |
Buy: 8 059 792 | Sell: 2 870 847 |
DiaMedica Therapeutics Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
DiaMedica Therapeutics Finanzas
Annual | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-30 000.00 (0.00 %) |
EPS: | $-0.600 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-30 000.00 (0.00 %) |
EPS: | $-0.600 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-25 000.00 (0.00 %) |
EPS: | $-0.520 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.650 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
DiaMedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico